Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of 7.70x is 33% above its 5-year average of 5.78x, around the middle of its 5-year range (-5.89x–14.21x).
57.44% above its 12-month average of 4.89x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): 5.13x.
INTEREST COVERAGE RATIO
7.70x
INTEREST COVERAGE RATIO AVG TTM
4.89x
INTEREST COVERAGE RATIO AVG 3Y
6.94x
INTEREST COVERAGE RATIO AVG 5Y
5.78x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+57.44%
CURRENT VS 3Y AVG
+10.95%
CURRENT VS 5Y AVG
+33.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
+220.78%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.41B
Interest Coverage Ratio
7.70x
TTM Avg
4.89x
3Y Avg
6.94x
5Y Avg
5.78x
Market Cap
$1.41B
Interest Coverage Ratio
-1753.94x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Interest Coverage Ratio
0.60x
TTM Avg
0.60x
3Y Avg
0.60x
5Y Avg
0.60x
Market Cap
$1.38B
Interest Coverage Ratio
-11.07x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
Interest Coverage Ratio
30.72x
TTM Avg
19.49x
3Y Avg
15.15x
5Y Avg
21.38x
Market Cap
$1.44B
Interest Coverage Ratio
-8.63x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Interest Coverage Ratio
1.06x
TTM Avg
1.06x
3Y Avg
1.45x
5Y Avg
1.23x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.41B | 7.70x | 4.89x | 6.94x | 5.78x |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.41B | -1753.94x | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.41B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 0.60x | 0.60x | 0.60x | 0.60x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | -11.07x | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 30.72x | 19.49x | 15.15x | 21.38x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -8.63x | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.45B | 1.06x | 1.06x | 1.45x | 1.23x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A | N/A | N/A | N/A |
Interest Coverage
7.7x
Debt/Equity
1.38
Current Ratio
1.20
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | 5.13x |
| 2026-03-31 | -5.89x |
| 2025-12-31 | 5.56x |
| 2025-09-30 | 10.08x |
| 2025-06-30 | 9.57x |
| 2025-03-31 | 10.50x |
| 2024-12-31 | 14.21x |
| 2024-09-30 | 3.73x |
| 2024-06-30 | 5.90x |
| 2024-03-31 | 4.76x |
| 2023-12-31 | 4.82x |
| 2023-09-30 | 4.72x |
| 2023-06-30 | 4.31x |
| 2023-03-31 | 3.04x |
| 2022-12-31 | 4.88x |
| 2022-09-30 | 6.75x |
| 2022-06-30 | -3.79x |
| 2022-03-31 | 3.70x |
| 2021-12-31 | -3.67x |
| 2021-09-30 | 3.32x |
| 2021-06-30 | 7.56x |
| 2021-03-31 | 4.48x |
| 2020-12-31 | 11.93x |
| 2020-09-30 | 23.32x |
| 2020-06-30 | 20.18x |
| 2020-03-31 | 10.60x |
| 2019-12-31 | -3.40x |
